JPS63138266A - Method for measuring antigen-antibody reaction - Google Patents
Method for measuring antigen-antibody reactionInfo
- Publication number
- JPS63138266A JPS63138266A JP61284878A JP28487886A JPS63138266A JP S63138266 A JPS63138266 A JP S63138266A JP 61284878 A JP61284878 A JP 61284878A JP 28487886 A JP28487886 A JP 28487886A JP S63138266 A JPS63138266 A JP S63138266A
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- concentration
- absorbance
- latex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 27
- 238000006243 chemical reaction Methods 0.000 title claims description 15
- 238000002835 absorbance Methods 0.000 claims abstract description 35
- 239000000427 antigen Substances 0.000 claims abstract description 33
- 102000036639 antigens Human genes 0.000 claims abstract description 33
- 108091007433 antigens Proteins 0.000 claims abstract description 33
- 239000002904 solvent Substances 0.000 claims abstract description 4
- 239000004816 latex Substances 0.000 abstract description 34
- 229920000126 latex Polymers 0.000 abstract description 34
- 239000002245 particle Substances 0.000 abstract description 19
- 230000035945 sensitivity Effects 0.000 abstract description 9
- 239000007788 liquid Substances 0.000 abstract description 5
- 238000011088 calibration curve Methods 0.000 abstract description 3
- 239000010419 fine particle Substances 0.000 abstract description 2
- 239000002131 composite material Substances 0.000 abstract 3
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 description 9
- 238000004220 aggregation Methods 0.000 description 8
- 230000004520 agglutination Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 2
- 238000002356 laser light scattering Methods 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 229920000785 ultra high molecular weight polyethylene Polymers 0.000 description 1
Landscapes
- Investigating Or Analysing Materials By Optical Means (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
Description
【発明の詳細な説明】 （イ）産業上の利用分野 本発明は、抗原−抗体反応の測定法に関する。[Detailed description of the invention] (b) Industrial application fields The present invention relates to a method for measuring antigen-antibody reactions.
さらに詳しくは、不発明は微細粒径の不溶性担体に抗体
（又は抗原）を相持させ、これに抗原（又は抗体）１−
反応させて、この抗原−抗体複合物に光を照射し、特定
の波長における吸光度を測定することにエフ抗原（又は
抗体）會定量する方法にに関する。More specifically, in the invention, an antibody (or antigen) is supported on an insoluble carrier having a fine particle size, and the antigen (or antibody) 1-
The present invention relates to a method for quantifying antigen (or antibody) by reacting the antigen-antibody complex, irradiating the antigen-antibody complex with light, and measuring the absorbance at a specific wavelength.
（ｃＱ従来の技術
近年、医療分野においては、病気の診断のために抗原あ
るいは抗体の濃度を定量的に検知することが重要な課題
となってきており、特に通常試料（血液など）中にＷｉ
資しか存在し力い成分例えば急性相反発物質であるＣＲ
Ｐや腫瘍マーカであるＡＰＰなどについて定量的に測定
できる高感度定量法の開発が課題となってきている。(cQ Conventional Technology) In recent years, in the medical field, quantitatively detecting the concentration of antigens or antibodies for disease diagnosis has become an important issue.
Strong components such as CR, which is an acute reciprocal
The development of a highly sensitive quantitative method that can quantitatively measure P and the tumor marker APP has become an issue.
従来、第６図に示すように抗体（又は抗原）ｋ担持させ
たラテックスを溶媒中に分散させ、これと抗原（又は抗
体）を反応させ、第７図に示すように、′ｐテックスの
凝集反応に伴なう濁度（ｇ＆光度）増２１［１ｔ−波長
６０（）＝ ２４００ ｎｍ で測定して、抗原（又は
抗体）？Ｉ一定量する方法が特許公開公報（昭５８−１
１５７５）に示され、実用化されている。Conventionally, as shown in Fig. 6, latex carrying an antibody (or antigen) is dispersed in a solvent, and the antigen (or antibody) is reacted with the latex, and as shown in Fig. 7, the agglutination of 'ptex Turbidity (g & light intensity) increase due to reaction 21 [1t - Wavelength 60 () = 2400 nm Measured with antigen (or antibody)? A method for producing a constant amount of I was published in the patent publication (1982
1575) and has been put into practical use.
また最近第８図に示すように凝集したラテックス粒子を
含む溶液上シーヌフロー中で１個１個の凝集塊に分け、
レーザ光源による光散乱検出法によＶ凝集の度合全解析
して抗原（又は抗体）ｔ一定量する方法が開発されてい
る。Recently, as shown in Fig. 8, a solution containing aggregated latex particles is separated into individual aggregates in Sineflow.
A method has been developed in which the total degree of V aggregation is analyzed using a light scattering detection method using a laser light source to determine a certain amount of antigen (or antibody).
（／１発明が解決しようとする問題点
しかしながら、−ｈ記の方法はつぎのような問題点があ
る。(/1 Problems to be Solved by the Invention However, the method described in -h has the following problems.
前者では、■ラテックス溶液自身の吸光度に比べて、ラ
テックス凝集による吸光度の変化が小さく。In the former case, ■The change in absorbance due to latex aggregation is small compared to the absorbance of the latex solution itself.
測定波長の選択により吸光度変化を大きく・しようとし
てもラテックス溶液自身の吸光度も大きくなってしまう
ため、 Ｓ／Ｎの改善にはならず、そのため第２図に示
すように、同一の反応液について。Even if you try to increase the change in absorbance by selecting the measurement wavelength, the absorbance of the latex solution itself will also increase, so the S/N ratio will not improve. Therefore, as shown in Figure 2, for the same reaction solution.
抗原−抗体反応開始後の一定時間後と、それから一定時
間経過後の２点について吸光度の変化分だけ全測定する
２点法の採用が必要となり、十分な反応時間後の吸光度
から試薬であるラテックス溶液のみの吸光度を差引く、
いわゆるエンドポイント法（１点法〕の採用かむつかし
く、Ｅ薬あるいは試料の分注から測定まで自動的にコン
トロールされる自動分析装置が必要となる。■吸光度は
粒子の大きさと、数によって決るためラテックス凝集の
度合と吸光度の変化とは１対１に対応せず。It is necessary to adopt a two-point method in which all changes in absorbance are measured at two points, one after a certain period of time after the start of the antigen-antibody reaction and the other after a certain period of time. Subtract the absorbance of the solution only,
It is difficult to adopt the so-called end-point method (one-point method), and an automatic analyzer is required to automatically control the process from dispensing the drug or sample to measuring it.■Absorbance is determined by the size and number of particles. There is no one-to-one correspondence between the degree of latex aggregation and the change in absorbance.
例えば第９図に示すように抗原の濃度の増加と共にラテ
ックスの凝集が起っているにもかかわらず。Even though latex aggregation occurs with increasing concentration of antigen, as shown for example in FIG.
ある濃！以上では吸光度が減少しはじめるという反転現
象が生ずる場合がある・０２点法においてはラテックス
濃度を減少させると凝集スピードが低下し、感度が悪く
なるので高価なラテックス試薬を多量に必要とする。な
どの問題かあ−】た。It’s so dark! In the above case, a reversal phenomenon may occur in which the absorbance starts to decrease.In the 02-point method, when the latex concentration is decreased, the aggregation speed decreases and the sensitivity deteriorates, so a large amount of expensive latex reagent is required. Is there a problem like that?
まｆｃ後者ではラテックスの凝集と測定結果が１対１に
対応し、ま友エンドポイント法の採用が可能であり反応
時間を長くするほど凝集が進み高感度となり、かつラテ
ックス濃度を減少させても感度は変らないなど前者の欠
点が改善されているが。In the latter case, there is a one-to-one correspondence between latex aggregation and measurement results, making it possible to use the Mayu endpoint method.The longer the reaction time, the more aggregation progresses, resulting in higher sensitivity, and even if the latex concentration is reduced. Although the drawbacks of the former have been improved, such as the sensitivity remaining the same.
シースフロー構造とすることが必要でかつ１個の粒子に
よる散乱光を検出するためレーザ光源が必要で専用装置
とならざるを得ないという問題点があった。There were problems in that it required a sheath flow structure and required a laser light source to detect light scattered by a single particle, requiring a dedicated device.
この発明は、かかる状況に鑑みなされたものであり専用
装置を用いなくても、汎用の分光光度計を用いて、エン
ドポイント法により抗原（又は抗体）の濃度′ｔ−潤定
する方法全提供しようとするものである。The present invention was made in view of this situation, and provides a complete method for determining the concentration of an antigen (or antibody) by an end point method using a general-purpose spectrophotometer without using a dedicated device. This is what I am trying to do.
（に）問題点を解決するための手段
かくしてこの発明によれば、抗原−抗体複合物を含有す
る被検液に光を照射して、２つの波長λ１、λ２におけ
る吸光度Ａλ１．ＡＵｚを求め、この値の変化に工９抗
原（又は抗体）の濃度を求めること全特徴とする抗原−
抗体反応の測定法が提供されるＯ
この発明の方法の最も特徴とする点は、異なる２波長の
吸光度比Ａλｌ／Ａλ２が被検液中に懸濁する粒子の平
均粒径の函数となることを利用するものであり、ラテッ
クスの凝集による平均粒径の増加音測定することに工９
．抗原（又は抗体ンの眞区全求めることができる。(2) Means for Solving the Problems Thus, according to the present invention, a test liquid containing an antigen-antibody complex is irradiated with light, and the absorbance at two wavelengths λ1 and λ2 is Aλ1. Determine AUz and calculate the concentration of the antigen (or antibody) from the change in this value.
A method for measuring an antibody reaction is provided. The most distinctive feature of the method of the present invention is that the absorbance ratio Aλl/Aλ2 at two different wavelengths is a function of the average particle diameter of particles suspended in the test liquid. It is a method that utilizes the technology, and it takes nine steps to measure the increase in average particle size due to latex agglomeration.
．． The entire antigen (or antibody) can be determined.
２波長の吸光度の比は懸濁液の濃度に関係なく。The ratio of absorbance at two wavelengths is independent of the concentration of the suspension.
粒子の屈折率と、測定波長に対する粒子の相対的な大き
さによるので、２波長の比をとる方法は。The method of calculating the ratio of the two wavelengths depends on the refractive index of the particle and the relative size of the particle to the measurement wavelength.
ラテックス濃度により、あまり影響されないので。It is not affected much by latex concentration.
エンドポイント法の採用が可能となる。It becomes possible to adopt the endpoint method.
各種粒径のポリスチレンラテックスについて数段階の濃
度の懸濁液について、 ３４Ｑｎｍ〜１１０００ｒ１の
吸光度を測定し、 １１０００ｎの吸光度Ａ１００Ｏに
対する他の波長の吸光度Ａλの比Ａλ／Ａ１００Ｏｆ求
めた結果全第１図に示す。第１図のＡｕ／Ａｔｏｏｏ
の値は、数段階の濃度の懸濁液についての平均値である
。各波長での吸光度はラテックス濃度と共に増加し穴が
。For suspensions of polystyrene latex of various particle sizes at several concentrations, the absorbance at 34Qnm to 11000r1 was measured, and the ratio Aλ/A100Of of the absorbance at other wavelengths to the absorbance A100O at 11000n was calculated, and the results are shown in Figure 1. show. Au/Atooo in Figure 1
The values are average values for suspensions of several concentrations. The absorbance at each wavelength increases with latex concentration.
その比Ａλ／Ａｔｏｏｏはほぼ一定であった。第１図の
結果！ ｖＩ Ｐ＋ トして９粒径Ａｓｏｏ／ Ａｌ
０００およばＡ６００／Ａ１００Ｏとの関係を求めた結
果を第２図に示す。第２図より１粒径の増加と共にＡｓ
ｏｏ／ＡｌｏｏｏおよびＡＦ１００／Ａ１００Ｏの値が
減少することが判る。The ratio Aλ/Atooo was almost constant. Results in Figure 1! vI P+ and 9 particle size Asoo/Al
FIG. 2 shows the results of determining the relationship between A600 and A600/A100O. From Figure 2, as the grain size increases, As
It can be seen that the values of oo/Alooo and AF100/A100O decrease.
以上より、抗体（又は抗原）を担持したラテックスの凝
集反応において、抗原（又は抗体）の濃度の増加と共に
凝集の度合も増加して平均粒径が増大した結果Ａｓｏｏ
／Ａ １０００あるいはＡ６００／Ａ１００Ｏの値が減
少することが予測でき、これにより抗原または抗体の定
量が可能と思われる。From the above, in the agglutination reaction of latex carrying antibodies (or antigens), as the concentration of antigens (or antibodies) increases, the degree of agglutination also increases and the average particle size increases.
It can be predicted that the value of /A 1000 or A600/A100O will decrease, and it seems possible to quantify the antigen or antibody.
この発明の方法に用いる２つの波長は、２波長が離れて
いるほど高感度となるが、短波長側では吸光度が大きく
なり、吸光度測定不能となる場合ｔあるので、使用する
ラテックスの大きさと濃度および抗原（又は抗体）の測
定濃度範囲によって最適条件を選択することが望ましい
。Regarding the two wavelengths used in the method of this invention, the farther apart the two wavelengths are, the higher the sensitivity becomes.However, the absorbance increases at the short wavelength side, and there are cases where absorbance cannot be measured. Therefore, the size and concentration of the latex used It is desirable to select optimal conditions depending on the measurement concentration range of the antigen (or antibody) and the antigen (or antibody).
通常の分光光度計においては、波長範囲は３３０〜１１
０００ｎ 、 ｅ光ｆｉｎは２ ＡＦ１８以下であるの
で。In a normal spectrophotometer, the wavelength range is 330-11
000n, e optical fin is 2 AF18 or less.
ラテックス試薬としては、ラテックスの直径が０１〜０
．３μｍで、 ５００ｎｍの吸光度が２ ＡＢ８以下に
なるような濃度に調整するのが望ましい。As a latex reagent, the diameter of the latex is 01 to 0.
．． It is desirable to adjust the concentration so that the absorbance at 500 nm is 2 AB8 or less at 3 μm.
（ホ）作 用
この発明によれば、抗体（又は抗原）ｔ−担持したラテ
ックス試薬と、濃度既知の抗原（又は抗体２の希釈系列
をもたして調整した各試料とを一定時間反応させたとき
の濃度とＡ１１％す２の関係を示す＠量線を求めておき
、この検量線を用いて濃度未知の試料中の抗原（又は抗
体）濃度を求めることになる。(e) Effect According to the present invention, a latex reagent carrying an antibody (or antigen) is reacted with each sample prepared with a dilution series of the antigen (or antibody 2) of known concentration for a certain period of time. A dose curve showing the relationship between the concentration and A11%2 is determined in advance, and this calibration curve is used to determine the antigen (or antibody) concentration in a sample of unknown concentration.
以下実施例によりこの発明の詳細な説明するが。The present invention will be explained in detail below with reference to Examples.
これによりこの発明が限定されるものではない。This invention is not limited by this.
（ハ）実ｆＩ例
第１表はＣＲＰ抗体を粒径約０．２１Ｏｍのラテックス
量した試薬と、 ＣＲＰ濃度既知の血清と全３７℃で反
応させた時の９０分後の各波長での吸光度Ａ３００〜Ａ
１０００と吸光度比Ａ！１００／Ａ６００およびＡ６０
０／Ａｌ ０００ ｆ示す。(c) Practical fI example Table 1 shows the absorbance at each wavelength after 90 minutes when a latex amount of CRP antibody with a particle size of approximately 0.21 Om was reacted with serum of known CRP concentration at 37°C. A300~A
1000 and absorbance ratio A! 100/A600 and A60
0/Al 000 f is shown.
第１表
また第３図にＣＲＰｆｉ度に対する各波長での吸光度の
検量線を示す。第３図においては添加するラテックス量
のバラツキによる測定点のバラツキが出ており、ｔ＊濃
度の増加に対して、 Ａ５υ０では吸光度の変化は大き
く、感度が高いことになるが。Table 1 and FIG. 3 show calibration curves of absorbance at each wavelength with respect to CRPfi degree. In Figure 3, there are variations in the measurement points due to variations in the amount of latex added, and as the t* concentration increases, the change in absorbance is large for A5υ0, which means that the sensitivity is high.
途中から吸光度が減少するという反転現象が起−）てい
る。Ａ１００Ｏではこのような現象はないが、ｒＪ＆光
度の変化が小さく、感度が低いため、低濃度でのＳ／Ｎ
が悪くなる・
第４図に本発明の例として、 ＣＲＰ濃度に対するＡ３
００／Ａ１００ＯおよびＡ３００／Ａ１００Ｏの検量線
を示す０第４図においてＡｓ０ｏ／Ａｔ０ＯＯおよびＡ
６００／Ａ１００Ｏｉｊ低濃度域でもその変化率が大き
く高感度であり、かつ濃度増加していっても反転現象は
起っていない。また２波長の吸光度の比をとることによ
り、ラテックス添加量のバラツキによる各吸光度のバラ
ツキが相殺されているので、測定点のバラツキもない。A reversal phenomenon occurs in which the absorbance decreases halfway through the process. A100O does not have this phenomenon, but the change in rJ & luminosity is small and the sensitivity is low, so the S/N at low concentration is low.
Figure 4 shows, as an example of the present invention, A3 for CRP concentration.
00/A100O and A300/A100O, As0o/At0OO and A
600/A100Oij Even in the low concentration range, the rate of change is large and the sensitivity is high, and no reversal phenomenon occurs even when the concentration increases. In addition, by taking the ratio of the absorbances of two wavelengths, variations in absorbance due to variations in the amount of latex added are offset, so there is no variation in measurement points.
第５図に、第２図に示したＡ６００／Ａ１００Ｏの値を
用いて抗原−抗体複合物の各濃度における結果を示すが
。FIG. 5 shows the results at each concentration of the antigen-antibody complex using the A600/A100O value shown in FIG.
これから本発明がラテックス凝集を適確にとらえること
ができる簡便でかつ有用な方法であることが判る。This shows that the present invention is a simple and useful method that can accurately detect latex aggregation.
（ト］発明の効果
本発明により、専用の自ｖＪｒＩ＆光度変化測定装置や
シースフローとレーザ光散乱法を用いた特殊な装置を用
いなくとも、汎用の分光光度計によシラテックス凝ｔＲ
ヲ利用し几抗原−抗体反応における抗原（又は抗体）の
濃度を精度よく高！ｅ、度に測定することが可能となる
。(G) Effects of the Invention The present invention enables the use of a general-purpose spectrophotometer to measure silatex tR without using a dedicated self-vJrI & light intensity change measuring device or a special device using a sheath flow and laser light scattering method.
Accurately increase the concentration of antigen (or antibody) in the antigen-antibody reaction by using e, it becomes possible to measure at once.
第１図は各種粒径のラテックス溶液の波長１１０００ｎ
の吸光度に対する他の波長での吸光度の比Ａλ％Ａｌｎ
ｏ。
全示す図、第２因はラテックスの粒径と、 Ａ３００／
Ａ１００ＯおよびΔ６ｏｏ／Ａｔｏｏｏの関係を示す図
、第３図・第４因・第５図はラテックス凝集反応を利用
してｅＲＰ濃度を測定する場合のＣＲＰ濃度と各波長で
の吸光度。
Ａ３００／Ａ１００ＯおよびＡＦ１００／Ａ１００Ｏ、
平均粒径の関係を示す図、第６図はラテックス凝集を利
用した抗原−抗体反応を示す図であり、第７図は吸光度
測定による従来のラテックス凝集反応？利用した抗原−
抗体反応の測定法、第８図にシースフローとレーザ光散
乱光法による従来のラテックス凝集反応を利用した抗原
−抗体反応の測定法、第９図は抗ぷ濃度と吸光度あるい
は凝集ラテックスの平均粒径の関係の１例を示す図であ
る。
特許出願人 株式会社島津製作所′ □゛代理人 弁理
士 武 石 端 彦 −１゛ａ吸（μｍ〕
０ １ ２，５４５
ＣＦ：ｒ（四／ｄＪり
￥３１刺
子４図
第５囲
凄１反も
第６図
第７図
第δ口Figure 1 shows the wavelength of latex solutions with various particle sizes at 11,000 nm.
The ratio of the absorbance at other wavelengths to the absorbance of Aλ%Aln
o. The second factor is the particle size of the latex and the A300/
A diagram showing the relationship between A100O and Δ6oo/Atoooo, and Figures 3, 4, and 5 show CRP concentration and absorbance at each wavelength when eRP concentration is measured using latex agglutination reaction. A300/A100O and AF100/A100O,
Figure 6 is a diagram showing the relationship between average particle size, and Figure 6 is a diagram showing an antigen-antibody reaction using latex agglutination, and Figure 7 is a diagram showing the conventional latex agglutination reaction using absorbance measurement. Antigen used
Method for measuring antibody reaction. Figure 8 shows a method for measuring antigen-antibody reaction using conventional latex agglutination reaction using sheath flow and laser light scattering method. Figure 9 shows antibody concentration and absorbance or average particles of aggregated latex. FIG. 3 is a diagram showing an example of the relationship between diameters. Patent applicant: Shimadzu Corporation' □゛Agent: Patent attorney Hajiko Takeishi -1゛a (μm) 0 1 2,545 CF: r (4/dJ ¥31 Sashiko 4 figure 5 encircling 1 anti Figure 6 Figure 7 Figure δ
Claims (1)
のを溶媒中に分散させ、これと抗原（又は抗体）を反応
させて生成する抗原−抗体複合物に異なる波長λ＿１、
λ＿２の光を照射し各波長の吸光度Ａλ＿１、Ａλ＿２
の比Ａλ＿１／Ａλ＿２を測定し、その値の変化の度合
により抗原（又は抗体）の濃度を測定することを特徴と
する抗原−抗体反応の測定法。An antigen-antibody complex produced by dispersing an antibody (or antigen) supported on a fine particle-sized insoluble carrier in a solvent and reacting it with the antigen (or antibody) has different wavelengths λ_1,
Irradiate light of λ_2 and absorbance of each wavelength Aλ_1, Aλ_2
A method for measuring an antigen-antibody reaction, characterized in that the ratio Aλ_1/Aλ_2 is measured, and the concentration of the antigen (or antibody) is determined based on the degree of change in that value.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61284878A JPH076985B2 (en) | 1986-11-28 | 1986-11-28 | Method for measuring antigen-antibody reaction |
| US07/124,997 US5093271A (en) | 1986-11-28 | 1987-11-24 | Method for the quantitative determination of antigens and antibodies by ratio of absorbances at different wavelengths |
| DE87402674T DE3787706T2 (en) | 1986-11-28 | 1987-11-26 | Method for the quantitative determination of antigens and antibodies. |
| EP87402674A EP0269526B1 (en) | 1986-11-28 | 1987-11-26 | Method of quantitative determination of antigens and antibodies |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61284878A JPH076985B2 (en) | 1986-11-28 | 1986-11-28 | Method for measuring antigen-antibody reaction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63138266A true JPS63138266A (en) | 1988-06-10 |
| JPH076985B2 JPH076985B2 (en) | 1995-01-30 |
Family
ID=17684204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61284878A Expired - Lifetime JPH076985B2 (en) | 1986-11-28 | 1986-11-28 | Method for measuring antigen-antibody reaction |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH076985B2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105510200A (en) * | 2015-11-23 | 2016-04-20 | 太原理工大学 | Nanoparticle suspension stability quantitative evaluation device |
| CN106596963A (en) * | 2016-05-27 | 2017-04-26 | 安徽伊普诺康生物技术股份有限公司 | Kit for measuring alpha fetoprotein |
| CN111795939A (en) * | 2020-07-21 | 2020-10-20 | 郑州安图生物工程股份有限公司 | Method for monitoring subpackaging uniformity of magnetic particle suspension |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5446829A (en) * | 1977-09-21 | 1979-04-13 | Hitachi Ltd | Nephelometry |
| JPS57168142A (en) * | 1981-03-19 | 1982-10-16 | Svenska Traeforskningsinst | Measurement of content of fine fiber particle in pulp fiber suspension |
| JPS5896251A (en) * | 1981-12-04 | 1983-06-08 | Asahi Medical Kk | Measuring method for antigen or antibody and reagent for measurement |
| JPS59100862A (en) * | 1982-12-01 | 1984-06-11 | Hitachi Ltd | Automatic analyzer |
-
1986
- 1986-11-28 JP JP61284878A patent/JPH076985B2/en not_active Expired - Lifetime
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5446829A (en) * | 1977-09-21 | 1979-04-13 | Hitachi Ltd | Nephelometry |
| JPS57168142A (en) * | 1981-03-19 | 1982-10-16 | Svenska Traeforskningsinst | Measurement of content of fine fiber particle in pulp fiber suspension |
| JPS5896251A (en) * | 1981-12-04 | 1983-06-08 | Asahi Medical Kk | Measuring method for antigen or antibody and reagent for measurement |
| JPS59100862A (en) * | 1982-12-01 | 1984-06-11 | Hitachi Ltd | Automatic analyzer |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105510200A (en) * | 2015-11-23 | 2016-04-20 | 太原理工大学 | Nanoparticle suspension stability quantitative evaluation device |
| CN105510200B (en) * | 2015-11-23 | 2018-04-13 | 太原理工大学 | A kind of device of quantitative assessment nanoparticle suspension stability |
| CN106596963A (en) * | 2016-05-27 | 2017-04-26 | 安徽伊普诺康生物技术股份有限公司 | Kit for measuring alpha fetoprotein |
| CN111795939A (en) * | 2020-07-21 | 2020-10-20 | 郑州安图生物工程股份有限公司 | Method for monitoring subpackaging uniformity of magnetic particle suspension |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH076985B2 (en) | 1995-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4157871A (en) | System for rate immunonephelometric analysis | |
| JP6367942B2 (en) | Method for detecting prozone effects in photometric assays | |
| US8673576B2 (en) | Multi-wavelength analyses of sol-particle specific binding assays | |
| JPS6365369A (en) | Method for measuring antigen-antibody reaction | |
| JPH0666808A (en) | Chromogen measurement method | |
| US5093271A (en) | Method for the quantitative determination of antigens and antibodies by ratio of absorbances at different wavelengths | |
| JPS63138266A (en) | Method for measuring antigen-antibody reaction | |
| JPS6281567A (en) | Quantification method using particle agglutination reaction | |
| JPH0635980B2 (en) | How to measure body fluid components | |
| US20030013083A1 (en) | Particle analysis as a detection system for particle-enhanced assays | |
| JPS63169564A (en) | Method for measuring antigen-antibody reaction with high sensitivity | |
| JPS63169563A (en) | Method for measuring antigen-antibody reaction with high sensitivity | |
| JPS6319560A (en) | Method for discriminating prozone in immunoreaction | |
| EP0433629B1 (en) | A method for the qualitative and quantitative determination of antibodies against bacterial antigens by means of the photometric measurement of agglutination | |
| JPH0233097B2 (en) | ||
| JPH0635976B2 (en) | Prozone determination method in immune reaction | |
| JPH01313737A (en) | Inspection device for body to be inspected | |
| JPH0599925A (en) | Method for measuring concentration of antigen or antibody | |
| JPS63247644A (en) | Method for measuring immune reaction | |
| JPH01270643A (en) | Method for examination of specimen | |
| JPH03274462A (en) | Apparatus and reagent for examining specimen | |
| JPH07117538B2 (en) | Antigen-antibody reaction determination method | |
| JPH0617916B2 (en) | Assay method for antigen-antibody reaction | |
| JPH01207663A (en) | Method and instrument for sample inspection | |
| JPS62116264A (en) | Method for quantification using particle agglutination reaction |